JPWO2020073121A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020073121A5 JPWO2020073121A5 JP2021516452A JP2021516452A JPWO2020073121A5 JP WO2020073121 A5 JPWO2020073121 A5 JP WO2020073121A5 JP 2021516452 A JP2021516452 A JP 2021516452A JP 2021516452 A JP2021516452 A JP 2021516452A JP WO2020073121 A5 JPWO2020073121 A5 JP WO2020073121A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- seq
- sequence
- amino acid
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002163 immunogen Effects 0.000 claims description 13
- 230000000240 adjuvant Effects 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 9
- 239000002158 endotoxin Substances 0.000 claims description 5
- 230000003308 immunostimulating Effects 0.000 claims description 4
- 239000002480 mineral oil Substances 0.000 claims description 4
- 235000010446 mineral oil Nutrition 0.000 claims description 4
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims description 4
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000038129 antigens Human genes 0.000 claims description 3
- 108091007172 antigens Proteins 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000002708 enhancing Effects 0.000 claims description 3
- -1 linker amino acid Chemical class 0.000 claims description 3
- 150000007949 saponins Chemical class 0.000 claims description 3
- 235000017709 saponins Nutrition 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K Aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H Aluminium sulfate Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 claims description 2
- 108010052285 Membrane Proteins Proteins 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 230000001580 bacterial Effects 0.000 claims description 2
- GZQKNULLWNGMCW-PWQABINMSA-J lipid A(4-) Chemical compound O1[C@H](CO)[C@@H](OP([O-])([O-])=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP([O-])([O-])=O)O1 GZQKNULLWNGMCW-PWQABINMSA-J 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 77
- 102000004965 antibodies Human genes 0.000 claims 62
- 108090001123 antibodies Proteins 0.000 claims 62
- 150000007523 nucleic acids Chemical class 0.000 claims 45
- 102100002977 CDR1 Human genes 0.000 claims 42
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 28
- 108020004707 nucleic acids Proteins 0.000 claims 25
- 150000001923 cyclic compounds Chemical class 0.000 claims 22
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 20
- 238000004166 bioassay Methods 0.000 claims 14
- 229920001184 polypeptide Polymers 0.000 claims 12
- 210000004027 cells Anatomy 0.000 claims 9
- 201000003356 synucleinopathy Diseases 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 108010027440 Immunoconjugates Proteins 0.000 claims 6
- 102000018748 Immunoconjugates Human genes 0.000 claims 6
- 102000003802 alpha-Synuclein Human genes 0.000 claims 6
- 108090000185 alpha-Synuclein Proteins 0.000 claims 6
- 208000009829 Lewy Body Disease Diseases 0.000 claims 4
- 201000002832 Lewy body dementia Diseases 0.000 claims 4
- 206010061536 Parkinson's disease Diseases 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 108010047814 Antigen-Antibody Complex Proteins 0.000 claims 3
- 108091003117 Bovine Serum Albumin Proteins 0.000 claims 2
- 229940098773 Bovine Serum Albumin Drugs 0.000 claims 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 2
- 108010078791 Carrier Proteins Proteins 0.000 claims 2
- 230000035693 Fab Effects 0.000 claims 2
- 208000001089 Multiple System Atrophy Diseases 0.000 claims 2
- YYGNTYWPHWGJRM-RUSDCZJESA-N Squalene Natural products C(=C\CC/C(=C\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\C)/C)/C YYGNTYWPHWGJRM-RUSDCZJESA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000001809 detectable Effects 0.000 claims 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 2
- 239000007764 o/w emulsion Substances 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- DRHZYJAUECRAJM-UHFFFAOYSA-N 6-{[8a-({[3-({5-[(4-{[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-3,5-dihydroxyoxan-2-yl)oxy]-3,4-dihydroxy-6-methyloxan-2-yl}oxy)-5-({5-[(5-{[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxy-6-methyloctanoyl)oxy]-3-hydroxy-6-methyloctanoyl}o Chemical compound O1C(CO)C(O)C(O)C1OC(C(C)CC)CC(O)CC(=O)OC(C(C)CC)CC(O)CC(=O)OC(C(C1OC2C(C(O)C(OC3C(C(OC4C(C(O)(CO)CO4)O)C(O)CO3)O)C(C)O2)O)O)C(C)OC1OC(=O)C1(C(CC2(C)C3(C)CCC4C5(C=O)C)O)CCC(C)(C)CC1C2=CCC3C4(C)CCC5OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(C(O)=O)C(O)C1OC1OCC(O)C(O)C1O DRHZYJAUECRAJM-UHFFFAOYSA-N 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 claims 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 claims 1
- 210000004408 Hybridomas Anatomy 0.000 claims 1
- 102000018358 Immunoglobulins Human genes 0.000 claims 1
- 108060003951 Immunoglobulins Proteins 0.000 claims 1
- 210000004470 MDP Anatomy 0.000 claims 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 210000002966 Serum Anatomy 0.000 claims 1
- 229940031439 Squalene Drugs 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000890 antigenic Effects 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000006249 magnetic particle Substances 0.000 claims 1
- 210000004962 mammalian cells Anatomy 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 108091008117 polyclonal antibodies Proteins 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000028993 immune response Effects 0.000 description 2
- 241000272478 Aquila Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000002238 attenuated Effects 0.000 description 1
- 239000011361 granulated particle Substances 0.000 description 1
- 230000002519 immonomodulatory Effects 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862742408P | 2018-10-07 | 2018-10-07 | |
| US62/742,408 | 2018-10-07 | ||
| US201862780599P | 2018-12-17 | 2018-12-17 | |
| US62/780,599 | 2018-12-17 | ||
| US201962820701P | 2019-03-19 | 2019-03-19 | |
| US62/820,701 | 2019-03-19 | ||
| US201962864060P | 2019-06-20 | 2019-06-20 | |
| US62/864,060 | 2019-06-20 | ||
| PCT/CA2019/051434 WO2020073121A1 (fr) | 2018-10-07 | 2019-10-07 | Épitopes spécifiques de conformation dans l'alpha-synucléine, anticorps dirigés contre ceux-ci et procédés associés |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022502369A JP2022502369A (ja) | 2022-01-11 |
| JPWO2020073121A5 true JPWO2020073121A5 (fr) | 2022-10-20 |
Family
ID=70163645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021516452A Pending JP2022502369A (ja) | 2018-10-07 | 2019-10-07 | α−シヌクレインの立体配座特異的エピトープ、それに対する抗体、およびそれに関連する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230051538A1 (fr) |
| EP (1) | EP3861015A4 (fr) |
| JP (1) | JP2022502369A (fr) |
| AU (1) | AU2019356804A1 (fr) |
| CA (1) | CA3148562A1 (fr) |
| WO (1) | WO2020073121A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201906947SA (en) | 2017-02-17 | 2019-08-27 | Bristol Myers Squibb Co | Antibodies to alpha-synuclein and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010002251A1 (fr) * | 2008-07-01 | 2010-01-07 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws | Vaccin contre un intermédiaire de repliement des amyloïdes |
| ES2564265T3 (es) * | 2009-03-09 | 2016-03-21 | Ramot At Tel-Aviv University Ltd. | Composiciones para prevención y tratamiento de enfermedades neurodegenerativas |
| EP2459214A1 (fr) * | 2009-07-30 | 2012-06-06 | Pfizer Vaccines LLC | Peptides tau antigéniques et leurs utilisations |
| CN102504016B (zh) * | 2011-12-08 | 2014-05-28 | 清华大学 | 淀粉样蛋白纤维性寡聚体构象型抗原表位多肽及其应用 |
| US20180346534A1 (en) * | 2015-11-09 | 2018-12-06 | The University Of British Columbia | C-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
| WO2017189959A1 (fr) * | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions pour le traitement de maladies |
| KR102550991B1 (ko) * | 2016-07-18 | 2023-07-04 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타에 대한 항체 |
| US10364286B2 (en) * | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
-
2019
- 2019-10-07 WO PCT/CA2019/051434 patent/WO2020073121A1/fr active Application Filing
- 2019-10-07 US US17/283,292 patent/US20230051538A1/en active Pending
- 2019-10-07 AU AU2019356804A patent/AU2019356804A1/en active Pending
- 2019-10-07 CA CA3148562A patent/CA3148562A1/fr active Pending
- 2019-10-07 JP JP2021516452A patent/JP2022502369A/ja active Pending
- 2019-10-07 EP EP19870641.8A patent/EP3861015A4/fr active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017137010A (ru) | Анти-сеасам6 антитела и их применения | |
| JP2019504615A5 (fr) | ||
| JP2019507580A5 (fr) | ||
| JP2019505166A5 (fr) | ||
| WO2015067768A1 (fr) | Anticorps monoclonal anti-strep-tag à haute affinité | |
| EP3596464B1 (fr) | Détection de cible à l'aide d'un anticorps monovalent | |
| JP2008515388A5 (fr) | ||
| JP3891542B2 (ja) | リン酸化部位に特異的な免疫学的反応体を生じさせる方法 | |
| JP2020522475A5 (fr) | ||
| CN113227148A (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
| US20220056118A1 (en) | Antibodies to misfolded tdp-43 and methods of use | |
| JPWO2020073121A5 (fr) | ||
| JP2022527812A (ja) | リラグルチドに対する抗体およびその使用 | |
| JP2019513004A5 (fr) | ||
| US20220340674A1 (en) | Method for the production of bispecific fcyriii x cd30 antibody construct | |
| JP2955082B2 (ja) | ヒトカルシトニンのｎ末端部分を特異的に認識するモノクローナル抗体 | |
| US20220242939A1 (en) | Antibody directed against the apoe amino-terminal fragment of 12kda | |
| EP3126839B1 (fr) | Agents utiles dans le diagnostic et la thérapie des troubles liés à l'agrégation de bêta-amyloïde et procédés de criblage | |
| CA2488127A1 (fr) | Anticorps contre le fragment f1.2 de la prothrombine, sa preparation et son utilisation | |
| CN117820473B (zh) | Aβ1-42特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用 | |
| JP7366411B2 (ja) | ヒトαディフェンシンＨＤ５を検出する方法及びキット、並びにこれらにおいて用いられる抗体 | |
| JP5448424B2 (ja) | ヒトＩｇＧのＦｃを含有するタンパク質の測定試薬 | |
| JP2012232948A5 (fr) | ||
| CN117229395A (zh) | 一种特异性结合降钙素的抗体及其用途 | |
| EP2762494A2 (fr) | Anticorps monoclonaux dirigés contre la protéine du prion de la tremblante (PrPSc) et leur utilisation |